搜索结果
靶点ID:TCMBANKGE004273
靶点别名:CPI-B; CST6; EPM1; EPM1A; PME; STFB; ULD
靶点描述:cystatin B
染色体:21
染色体位置:21q22.3
靶点类型:protein-coding
HERB_ID:-
HGNC_Link:2482
OMIM_Link:601145
Ensembl_Link:ENSG00000160213
靶点对应的植物
| ID | 拉丁名 | 药名 | 药用植物名 | 功能与主治 | 来源 | 药用部位 | 使用民族 |
|---|
靶点对应的化合物
| 化合物ID | 化合物名 | 别名 | 分子式 | 分子质量 | Smiles |
|---|
| TCMBANKIN058053 | diallyl trisulfide | DSSTox_CID_25972; SCHEMBL562845; CHEMBL123040; 3-(prop-2-enyltrisulfanyl)-1-propene; Trisulfide,di-2-propen-1-yl; Prop-2-enyl-trithio prop-2-ene; 1,3-Diallyltrisulfane; DSSTox_GSID_45972; 4,5,6-Trithia-1,8-nonadiene; Allyl trisulfide, 8CI; FEMA 3265; MolPort-003-665-652; DTXSID9045972; 050D875; Allitridin; 2050-87-5; Trisulfide, di-2-propenyl (9CI); NSC651936; allitridin; diallylTrisulfide; A814621; Diallyl trisulfide, >=98% (HPLC); EINECS 218-107-8; BDBM50318454; 8008-99-9; AI3-35127; C6H10S3; RT-003641; Diallyltrisulfide; CJ-26310; diallyltrisulfane; CTK3J7216; 1,3-Diallyltrisulfane #; CCG-230978; CCRIS 3251; C-51303; KS-00000ZOW; M259; bis(prop-2-en-1-yl)trisulfane; Tox21_111500; AC1L27PI; Garlic oil; BRN 1745734; Jsp004197; FT-0626632; Diallyl trisulphide; allitridum; FT-0624607; SPECTRUM1505014; 0-01-00-00441 (Beilstein Handbook Reference); (CH2=CHCH2S)2S; DSSTox_RID_81264; UBAXRAHSPKWNCX-UHFFFAOYSA-N; Diallyl trisulfide, >=97% (HPLC); AKOS006282485; ALLYL TRISULFIDE; UNII-609MRV3T0J component UBAXRAHSPKWNCX-UHFFFAOYSA-N; 3-(allyltrisulfanyl)prop-1-ene; Q-100252; CAS-2050-87-5; DB-003624; CHEBI:78492; Dasuansu; NCGC00095290-01; Prop-2-enyl prop-2-enylthio disulfide; NCGC00095290-02; AB1006016; KB-49701; FEMA No. 3265; NSC 651936; Diprop-2-en-1-yltrisulfane; diallyl trisulfide ; 0ZO1U5A3XX; NSC-651936; BC216501; UNII-0ZO1U5A3XX; I09-0167; Trisulfide, di-2-propenyl; Diallyl trisulfide; AN-19812; Di-2-propenyl trisulfide; FCH834827; 1,3-Diallyltrisulfane; LS-2660; 3-(prop-2-enyltrisulfanyl)prop-1-ene; DSSTox_CID_25972; SCHEMBL562845; CHEMBL123040; 3-(prop-2-enyltrisulfanyl)-1-propene; Trisulfide,di-2-propen-1-yl; Prop-2-enyl-trithio prop-2-ene; 1,3-Diallyltrisulfane; DSSTox_GSID_45972; 4,5,6-Trithia-1,8-nonadiene; Allyl trisulfide, 8CI; FEMA 3265; MolPort-003-665-652; AIDS008801; DTXSID9045972; 050D875; Allitridin; 2050-87-5; 3-prop-2-enylsulfanyldisulfanylprop-1-ene; Trisulfide, di-2-propenyl (9CI); AIDS-008801; NSC651936; A814621; Diallyl trisulfide, >=98% (HPLC); EINECS 218-107-8; BDBM50318454; 8008-99-9; AI3-35127; C6H10S3; RT-003641; Diallyltrisulfide; CJ-26310; diallyltrisulfane; CTK3J7216; 1,3-Diallyltrisulfane #; CCG-230978; CCRIS 3251; C-51303; KS-00000ZOW; M259; bis(prop-2-en-1-yl)trisulfane; Tox21_111500; AC1L27PI; Garlic oil; BRN 1745734; Jsp004197; FT-0626632; Diallyl trisulphide; allitridum; FT-0624607; SPECTRUM1505014; 0-01-00-00441 (Beilstein Handbook Reference); (CH2=CHCH2S)2S; DSSTox_RID_81264; UBAXRAHSPKWNCX-UHFFFAOYSA-N; Diallyl trisulfide, >=97% (HPLC); AKOS006282485; ALLYL TRISULFIDE; UNII-609MRV3T0J component UBAXRAHSPKWNCX-UHFFFAOYSA-N; 3-(allyltrisulfanyl)prop-1-ene; Q-100252; CAS-2050-87-5; DB-003624; CHEBI:78492; Dasuansu; NCGC00095290-01; 3-allylsulfanyldisulfanylprop-1-ene; FEMA No. 3533; Prop-2-enyl prop-2-enylthio disulfide; NCGC00095290-02; AB1006016; 3-(allylthio)disulfanylprop-1-ene; KB-49701; FEMA No. 3265; NSC 651936; Diprop-2-en-1-yltrisulfane; 0ZO1U5A3XX; NSC-651936; BC216501; UNII-0ZO1U5A3XX; I09-0167; Trisulfide, di-2-propenyl; Diallyl trisulfide; AN-19812; Di-2-propenyl trisulfide; FCH834827; 1,3-Diallyltrisulfane; LS-2660; 3-(prop-2-enyltrisulfanyl)prop-1-ene; allitridin | C6H10S3 | 178.34 | C=CCSSSCC=C |
| TCMBANKIN060889 | delta(9)-tetrahydrocannabinol | C21H30O2 | 314.5 g/mol | CCCCCC1=CC(=C2C3C=C(CCC3C(OC2=C1)(C)C)C)O | |
| TCMBANKIN060892 | tetrahydrocannabinol delta8 | CCCCCC1=CC2=C(C3C=C(CCC3C(O2)(C)C)C)C(=C1)O | |||
| TCMBANKIN061671 | dl-tetrahydropalmatine | dl-tetrahydropalmatine;AIDS002241; 84-38-8; 13a-alpha-Berbine, 2,3,9,10-tetramethoxy-; CHEBI:16563; 6H-Dibenzo(a,g)quinolizine, 5,8,13,13a-tetrahydro-2,3,9,10-tetramethoxy-, (S)-; (S)-5,8,13,13a-Tetrahydro-2,3,9,10-tetramethoxy-6H-dibenzo(a,g)quinolizine; AIDS-002241; C02890; Hyndarine; (-)-Corydalis; 4880-82-4 (HCL); NSC36363 (HCL); InChI=1/C21H25NO4/c1-23-18-6-5-13-9-17-15-11-20(25-3)19(24-2)10-14(15)7-8-22(17)12-16(13)21(18)26-4/h5-6,10-11,17H,7-9,12H2,1-4H3/t17-/m0/s; 5,8,13,13a-Tetrahydro-2,3,9,10-tetramethoxy-6H-dibenzo(a,g)quinolizine; 5,8,13,13a(S)-Tetrahydro-2,3,9,10-tetramethoxy-6H-dibenzo[a,g]quinolizine; 2-(2,3-Dimethoxy-benzyl)-1-ethyl-6,7-dimethoxy-1,2,3,4-tetrahydro-isoquinoline; BB_NC-1018; Gindarine; Tetrahydropalmatine (6CI); Berbine, 2,3,9,10-tetramethoxy- (8CI); Tetrahydropalmatine; l-Tetrahydropalmatine; (S)-Tetrahydropalmatine; Caseanine; 6H-Dibenzo(a,g)quinolizine, 5,8,13,13a-tetrahydro-2,3,9,10-tetramethoxy-; Rotundine; (13aS)-2,3,9,10-tetramethoxy-6,8,13,13a-tetrahydro-5H-isoquinolino[2,1-b]isoquinoline; 483-14-7; (13aS)-2,3,9,10-tetramethoxy-5,8,13,13a-tetrahydro-6H-isoquino[3,2-a]isoquinoline; 6H-dibenzo[a,g]quinolizine, 5,8,13,13a-tetrahydro-2,3,9,10-tetramethoxy-, (13aS)-; (-)-Tetrahydropalmatine;2,3,9,10-Tetramethoxy-6,8,13,13a-tetrahydro-5H-isoquinolino[3,2-a]isoquinoline hydrochloride; 2,3,9,10-Tetramethoxy-5,8,13,13a-tetrahydro-6H-isoquino[3,2-a]isoquinoline hydrochloride; AKOS024399264; MolPort-002-321-247; Berbine,3,9,10-tetramethoxy-, hydrochloride; NSC-132057; NSC-209411; 2,3,9,10-Tetramethoxyberbine hydrochloride; 6024-85-7; CHEMBL1412574; NSC132058; Palmatine, hydrochloride, (.+-.)-; 6H-Dibenzo[a, 5,8,13,13a-tetrahydro-2,3,9,10-tetramethoxy-, hydrochloride, (R)-; Tetrahydropalmatine hydrochloride; 024T857; C-55689; MCULE-7006385138; Palmatine, hydrochloride, (+)-; A832652; 6H-Dibenzo[a, 5,8,13,13a-tetrahydro-2,3,9,10-tetramethoxy-, hydrochloride; MLS000029596; Ambotz6024-85-7; 2506-20-9; FT-0698667; 6H-Dibenzo[a, 5,8,13,13a-tetrahydro-2,3,9,10-tetramethoxy-, hydrochloride, (.+-.)-; WLN: T D6 B666 KN&TT&J GO1 HO1 PO1 QO1 &GH; AC1O7ERI; NSC132057; NSC-132058; MLS002535962; AK310574; 2,3,9,10-tetramethoxy-6,8,13,13a-tetrahydro-5H-isoquinolino[2,1-b]isoquinoline hydrochloride; AC-8031; 13a.beta.-Berbine,3,9,10-tetramethoxy-, hydrochloride; Berbine,3,9,10-tetramethoxy-, hydrochloride, (+)-; NSC209411; Berbine,3,9,10-tetramethoxy-, hydrochloride, (.+-.)-; 3,4,10,11-tetramethoxy-7,8,12b,13-tetrahydro-5H-6000000-azatetraphene hydrochloride; SCHEMBL3502167; AC1Q3C4E; D-Tetrahydropalmatine hydrochloride; Tetrahydropalmatine, HCl; SMR000008833;(13aR)-2,3,9,10-tetramethoxy-6,8,13,13a-tetrahydro-5H-isoquinolino[2,1-b]isoquinoline;Hyndarin;tetrahydropalmatine;L-tetrahydropalmatine;STOCK1N-14407 | C21H25NO4 | 355.4 g/mol | COC1=C(C2=C(CC3C4=CC(=C(C=C4CCN3C2)OC)OC)C=C1)OC |
靶点对应的疾病
| 疾病ID | 疾病名 | MeSH名 | HPO名 | UMLS名 | 疾病类型 |
|---|
| TCMBANKDI000064 | Digestive System Diseases | - | Disease or Syndrome | group | |
| TCMBANKDI000088 | Neoplasms; Respiratory Tract Diseases | Neoplasm; Abnormality of the respiratory system | Neoplastic Process | group | |
| TCMBANKDI000166 | - | - | Neoplastic Process | disease | |
| TCMBANKDI002657 | Pathological Conditions, Signs and Symptoms; Nervous System Diseases; Otorhinolaryngologic Diseases | - | Disease or Syndrome | disease | |
| TCMBANKDI003372 | Neoplasms; Nervous System Diseases | - | Neoplastic Process | disease | |
| TCMBANKDI003411 | - | - | Disease or Syndrome | disease | |
| TCMBANKDI004394 | Neoplasms; Nervous System Diseases | - | Neoplastic Process | disease | |
| TCMBANKDI005868 | - | Abnormality of the nervous system | Finding | phenotype | |
| TCMBANKDI006084 | Neoplasms; Nervous System Diseases | - | Neoplastic Process | disease | |
| TCMBANKDI009231 | Pathological Conditions, Signs and Symptoms; Infections | Abnormality of the immune system | Disease or Syndrome | disease | |
| TCMBANKDI009912 | Pathological Conditions, Signs and Symptoms | Abnormality of metabolism/homeostasis | Sign or Symptom | phenotype | |
| TCMBANKDI010896 | Nervous System Diseases | Abnormality of the nervous system | Disease or Syndrome | group | |
| TCMBANKDI010939 | Pathological Conditions, Signs and Symptoms; Eye Diseases; Nervous System Diseases; Behavior and Behavior Mechanisms; Cardiovascular Diseases | - | Congenital Abnormality | disease | |
| TCMBANKDI012424 | Pathological Conditions, Signs and Symptoms; Neoplasms | - | Pathologic Function | phenotype | |
| TCMBANKDI016612 | Mental Disorders | Abnormality of the nervous system | Mental or Behavioral Dysfunction | phenotype | |
| TCMBANKDI016946 | Congenital, Hereditary, and Neonatal Diseases and Abnormalities; Digestive System Diseases; Respiratory Tract Diseases | - | Disease or Syndrome | disease | |
| TCMBANKDI017024 | Neoplasms; Respiratory Tract Diseases | - | Neoplastic Process | disease | |
| TCMBANKDI020119 | Mental Disorders | Abnormality of the nervous system | Finding | phenotype | |
| TCMBANKDI020449 | Skin and Connective Tissue Diseases | Abnormality of the integument | Pathologic Function | phenotype | |
| TCMBANKDI023464 | Nervous System Diseases | Abnormality of the nervous system | Disease or Syndrome | disease | |
| TCMBANKDI023751 | Pathological Conditions, Signs and Symptoms; Nervous System Diseases | Abnormality of the musculature | Finding | phenotype | |
| TCMBANKDI025420 | Digestive System Diseases; Neoplasms | Abnormality of the digestive system; Neoplasm | Neoplastic Process | disease | |
| TCMBANKDI026165 | Nervous System Diseases | - | Disease or Syndrome | disease | |
| TCMBANKDI026930 | Neoplasms; Nervous System Diseases | - | Neoplastic Process | disease | |
| TCMBANKDI030540 | Neoplasms; Female Urogenital Diseases and Pregnancy Complications; Endocrine System Diseases | Abnormality of the genitourinary system; Neoplasm | Neoplastic Process | disease | |
| TCMBANKDI031297 | Cardiovascular Diseases | - | Disease or Syndrome | group | |
| TCMBANKDI031570 | - | Abnormality of the nervous system | Mental or Behavioral Dysfunction | disease |
滇IICP备16009434号-1 |
Dai SX Lab